⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294976 | 0.80 | — | — | |
| SCHEMBL3354761 | 0.70 | TP53 (0.33) | — | |
| SCHEMBL4658870 | 0.64 | — | — | |
| SCHEMBL3537101 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL4701756 | 0.60 | — | — | |
| SCHEMBL4598897 | 0.60 | — | — | |
| SCHEMBL28570326 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL12479156 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL3963500 | 0.60 | — | — | |
| SCHEMBL8632628 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367111-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-109593096-A | Tricyclic heterocyclic as BET protein inhibitor | 因赛特公司 | 2019-04-09 | — | — | CN | disclosed |
| CN-105164131-B | Tricyclic heterocycles as BET protein inhibitors | 因赛特公司 | 2018-12-28 | — | — | CN | disclosed |
| EP-2220078-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | Amgen, Inc (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |